دورية أكاديمية
أعرض في EDS

Predictive Nomogram and Propensity Score Matching in Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract: A US Population-Based Clinical Outcome Study.

التفاصيل البيبلوغرافية
العنوان: Predictive Nomogram and Propensity Score Matching in Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract: A US Population-Based Clinical Outcome Study.
المؤلفون: Yasinzai AQK; Department of Medicine, Bolan Medical College, Quetta 83700, Pakistan., Khan M; Department of Medicine, Marshfield Clinic, Wisconsin, WI 54449, USA., Chandasir A; Medical College of Georgia, Augusta University, Augusta, GA 30912, USA., Olavarria-Bernal D; Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Sohail AH; Department of Surgery, University of New Mexico, Albuquerque, NM 87131, USA., Wali A; Department of Medicine, Bolan Medical College, Quetta 83700, Pakistan., Tareen B; Department of Medicine, Bolan Medical College, Quetta 83700, Pakistan., Nguyen T; Medical College of Georgia, Augusta University, Augusta, GA 30912, USA., Fox AD; Department of Hematology-Oncology, Augusta University, Augusta, GA 30912, USA., Goyal A; Department of Medicine, Seth GS Medical College and KEM Hospital, Mumbai 400012, India., Khan I; Department of Medicine, Insight Hospital and Medical Center, Chicago, IL 60616, USA., Waheed A; Department of Surgery, San Joaquin General Hospital, San Joaquin, CA 95231, USA., Iqbal A; Department of Medicine, Mercy Hospital, Ardmore, OK 73401, USA., Karki NR; Division of Hematology-Oncology, University of South Alabama, Mobile, AL 36688, USA., Das K; Department of Medicine, Division of Gastroenterology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Ullah A; Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
المصدر: Cancers [Cancers (Basel)] 2024 May 24; Vol. 16 (11). Date of Electronic Publication: 2024 May 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: Neuroendocrine carcinomas (NECs) of the tubular gastrointestinal tract (GI-NECs) are rare and associated with worse clinical outcomes. This population-based study aims to highlight key demographics, clinicopathological factors, and survival outcomes in the US population. Methods: Data from 10,387 patients with GI-NECs were extracted from the Surveillance, Epidemiology, and End Result (SEER) database from 2000 to 2020. Results: Most patients were >40 years old at the time of presentation with a median age of 63 years old, with almost equal ethnic distribution per US population data. The most common primary tumor site was the small intestine (33.6%). The metastatic spread was localized in 34.8%, regional in 27.8%, and distant in 37.3% of cases, and the liver was the most common site of metastasis (19.9%) in known cases of metastases. Most NEC patients underwent surgery, presenting the highest 5-year overall survival of 73.2% with a 95% confidence interval (CI) (95% CI 72.0-74.4%), while chemotherapy alone had the lowest 5-year survival of 8.0% (95% CI 6.4-10.0%). Compared to men, women had a superior 5-year survival rate of 59.0% (95% CI 57.6-60.5%). On multivariate analysis, age > 65 (HR 2.49, 95% CI 2.36-2.54%, p ≤ 0.001), distant metastasis (HR 2.57, 95% CI 2.52-2.62%, p ≤ 0.001), tumor size > 4 mm (HR 1.98, 95%, CI 1.70-2.31%, p ≤ 0.001), esophageal (HR 1.49, 95% CI 0.86-2.58%, p ≤ 0.001), transverse colon (HR 1.95, 95% CI 1.15-3.33%, p ≤ 0.01), descending colon (HR 2.12, 95% CI 1.12, 3.97%, p = 0.02) anorectal sites, and liver or lung metastases were associated with worse survival. Surgical intervention and tumors located in the small intestine or appendix showed a better prognosis. Conclusion: GI-NECs are a group of rare malignancies associated with a poor prognosis. Therefore, epidemiological studies analyzing national databases may be the best alternative to have a more comprehensive understanding of this condition, assess the impact of current practices, and generate prognosis tools.
References: Endocr Relat Cancer. 2022 Nov 02;29(12):665-679. (PMID: 36165930)
J Neuroendocrinol. 2023 Apr;35(4):e13256. (PMID: 37017614)
Endocr Relat Cancer. 2017 Sep;24(9):R315-R334. (PMID: 28710117)
J Gastroenterol. 2010 Feb;45(2):234-43. (PMID: 20058030)
Am J Surg. 2023 Jan;225(1):58-65. (PMID: 36216612)
Nat Commun. 2021 Jul 29;12(1):4612. (PMID: 34326338)
Medicine (Baltimore). 2016 Apr;95(15):e3308. (PMID: 27082572)
Endocr Relat Cancer. 2023 Jul 11;30(8):. (PMID: 37184955)
Visc Med. 2017 Oct;33(5):324-330. (PMID: 29177160)
Cancer Epidemiol. 2019 Dec;63:101598. (PMID: 31539715)
Adv Clin Exp Med. 2020 Feb;29(2):265-270. (PMID: 32091671)
Neuroendocrinology. 2016;103(2):186-94. (PMID: 26731334)
Cancer. 2014 Sep 15;120(18):2814-23. (PMID: 24771552)
Curr Oncol Rep. 2021 Mar 14;23(4):43. (PMID: 33719003)
Surg Clin North Am. 2020 Jun;100(3):635-648. (PMID: 32402306)
Ann Oncol. 2013 Jan;24(1):152-60. (PMID: 22967994)
Eur Radiol. 2013 Feb;23(2):400-7. (PMID: 22932740)
Ann Oncol. 2020 Jul;31(7):844-860. (PMID: 32272208)
Head Neck. 2009 Dec;31(12):1634-46. (PMID: 19536850)
Endocr Pathol. 2021 Mar;32(1):192-210. (PMID: 33433884)
Am J Surg Pathol. 2016 Sep;40(9):1192-202. (PMID: 27259015)
Cancers (Basel). 2021 Feb 05;13(4):. (PMID: 33562726)
Endocr Pathol. 2022 Mar;33(1):115-154. (PMID: 35294740)
Endocr Rev. 2019 Apr 1;40(2):506-536. (PMID: 30657883)
Endocr Relat Cancer. 2021 Nov 11;29(1):1-14. (PMID: 34647903)
Cancer. 2018 Feb 15;124(4):807-815. (PMID: 29211313)
J Natl Cancer Inst. 2017 Jan 27;109(5):. (PMID: 28130474)
CMAJ. 2017 Mar 13;189(10):E398-E404. (PMID: 28385820)
Cancer. 2015 Feb 15;121(4):589-97. (PMID: 25312765)
Oncologist. 2019 Jul;24(7):911-920. (PMID: 30482824)
BMC Cancer. 2020 Nov 14;20(1):1104. (PMID: 33189127)
World J Gastroenterol. 2017 Jul 21;23(27):4847-4855. (PMID: 28785139)
فهرسة مساهمة: Keywords: SEER; chemotherapy; neuroendocrine carcinoma; prognosis
تواريخ الأحداث: Date Created: 20240619 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC11171326
DOI: 10.3390/cancers16111998
PMID: 38893117
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16111998